Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

By J. Larosa, S. Grundy, D. Waters, C. Shear, P. Barter, J. Fruchart, A. Gotto, H. Greten, J. Kastelein, J. Shepherd and 1 more. New England Journal of Medicine, 2005

3,477 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/2c1764090612c7f9da39d79ca43d8bc3f7b4194e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Lloyd‐Jones
2. R. Eckel
3. J. Liao
4. N. Stone
5. Daniel Levy
6. M. Simoons
7. K. Thygesen
8. K. Fox

Citations in the corpus

• High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. (2005, background): “ment in prognosis with respect to cardiovascular disease was demonstrated.(3) In that study, however, the benefit of reduced cardiovascular mortality appeared to have been offset by a higher number of deaths due to noncardiovascular causes.”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “1 Primary prevention of stroke The use of statin therapy in adults at high risk of CVD due to LDL-C or other CV risk factors, including arterial hypertension, as well as in the setting of established CVD, reduces the risk of ischaemic stroke or TIA.(64,69,128,330,422) .”